37 Shah GB, Sharma S, Mehta AA, Goyal RK. Oculohypotensive Effect of Angiotensin- Converting Enzyme Inhibitors in Acute and Chronic Models of Glaucoma. J Cardiovasc Pharmacol ,2000;36(2):169-175

38 Naveh N, Kaplan-Messas A, Marshall J. Mechanism related to reduction of intraocular pressure by melanocortins in rabbits. Br J Ophthalmol ,2000;84(12):1411-1414

39 Serle JB, Wang RF, Peterson WM, Plourde R, Yerxa BR. Effect of 5-MCA-NAT, a putative melatonin MT3 receptor agonist, on intraocular pressure in glaucomatous monkey eyes. J Glaucoma ,2004;13(5):385-388

40 Li ZY, Chang JH, Milam AH. A gradient of basic fibroblast growth factor in rod photoreceptors in the normal human retina. Vis Neurosci ,1997;14(4):671-679

41 Richardson PM. Ciliary neurotrophic factor: a review. Pharmacol Ther. Pharmacol Ther ,1994;63(2):187-198

42 Mansour-Robaey S, Clarke DB, Wang YC, Bray GM, Aguayo AJ. Effects of ocular injury and administration of brain-derived neurotrophic factor on survival and regrowth of axotomized retinal ganglion cells. Proc Nat Acad Sci USA ,1994;91(5):1632-1636

43 Burren CP, Berka JL, Edmondson SR, Werther GA, Batch JA. Localization of mRNAs for insulin-like growth factor-I (IGF-I), IGF-I receptor, and IGF binding proteins in rat eye. Invest Ophthalmol Vis Sci ,1996;37(7):1459-1468

44 Neufeld AH. Nitric Oxide: A Potential Mediator of Retinal Ganglion Cell Damage in Glaucoma. Surv Ophthalmol ,1999;43(Suppl 1 ):129-135

45 Pellegrini-Giampietro DE, Cherici G, Alesiani M, Carla V, Moroni F. Excitatory amino acid release and free radical formation may cooperate in the genesis of ischemia-induced neuronal damage. J Neurosci ,1990;10(3):1035-1041

46 Neacsu A, Oprean C, Curea M, Tuchila G, Trifu M. Neuroprotection with carotenoids in glaucoma. Ophthalmologia ,2003;59 (4):70-75

47 Reed JC. Apoptosis-based therapies. Nat Rev Drug Discov ,2002;1:111-121

48 Thiagarajan G, Chandani S, Harinarayana Rao S, Samuni AM, Chandrasekaran K, Balasubramanian D . Molecular and cellular assessment of Ginkgo Biloba Extract as a possible ophthalmic drug. Exp Eye Res ,2002;75(4):421-430

49 Tsai JC, Wu L, Worgul B, Forbes M, Cao J. Intravitreal administration of erythropoietin and preservation of retinal ganglion cells in an experimental rat.model of glaucoma. Curr Eye Res. ,2005;30(11):1025-1031

50 Zheng H, Youdim MB, Weiner LM, Fridkin M. Novel potential neuroprotective agents with both iron chelating and amino acid-based derivatives targeting central nervous system neurons. Biochem Pharmacol ,2005;70(11):1642-1652

51 Garhofer G, Resch H, Lung S, Weigert G, Schmetterer L. Intravenous Administration of L-Arginine Increases Retinal and Choroidal Blood Flow. Am J Ophthalmol ,2005;140(1):69-76

52 Koksal M, Ozdemir H, Kargi S, Yesilli C, Tomac S, Mahmutyazicioglu K, Mungan A. The effects of sildenafil on ocular blood flow. Acta Ophthalmol Scand ,2005;83(3):355-359

53 Zou YH, Chiou GGY. New idens for medical therapy of glaucoma in the fature. Int J Ophthalmol (Guoji Yanke Zazhi) ,2005;5(3):411-422

54 van der Valk R, Webers CA, Schouten JS, Zeegers MP, Hendrikse F, Prins MH. Intraocular Pressure-Lowering Effects of All Commonly Used Glaucoma Drugs A Meta-analysis of Randomized Clinical Trials. Ophthalmology ,2005;112(7):1177-1185

上一页  [1] [2] [3] [4] [5] [6] [7] [8]